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Abstract
Purpose of Review Familial hypercholesterolemia (FH) is often perceived and described as underdiagnosed and undertreated,
though effective treatment of FH is available. Owing to the mentioned facts, it is ever more imperative to screen and treat FH
patients. Subsequent to the identification of patients, the project focuses on the improvement of their prognoses. The ScreenPro
FH project was established as a functional international network for the diagnosis, screening, and treatment of FH. Individual
countries were assigned goals, e.g., to define the actual situation and available treatment. With “central support,” more centers
and countries participated in the project. Subsequently, individual countries reported the results at the beginning and end of the
project. Collected data were statistically evaluated.
Recent Findings The increasing number of patients in databases, from 7500 in 2014 to 25,347 in 2018, demonstrates the
improvement in overall effectiveness, as well as an increase in the number of centers from 70 to 252. Before all, LDL-C decreased
by 41.5% and total cholesterol by 32.3%. As data from all countries and patients were not available at the time of the analysis,
only those results from 10 countries and 5585 patients at the beginning of the project and at the time of writing are included.
Summary Our data are quite positive. However, our results have only limited validity. Our patients are far from the target levels
of LDL-C. The situation can be improved with the introduction of new therapy, PCSK9-i, evolocumab, and alirocumab.
International cooperation improved the screening of FH and finally led to an improvement in cardiovascular risk.
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Introduction
Familial hypercholesterolemia (FH) is still, despite great recent
progress, underestimated, underdiagnosed, and undertreated,
and it represents a significant problem as a common risk factor
for the premature development of coronary heart disease
(CHD) [1, 2••]. FH is a monogenic disease transmitted through
autosomal dominant inheritance and stems from either an
LDL-R defect, familial defective apolipoprotein B-100
(FDB), or PCSK9 gain-of-function mutations [3, 4•].
FH is an example of a disease that, by its very nature,
allows us to study the relationship between lipid metabolism,
especially LDL-cholesterol (LDL-C), and atherosclerosis, as
well as the premature manifestation of cardiovascular disease
(CVD) [1, 5]. FH occurs with a frequency of 1:250–1:500 and
is one of the most common congenital metabolic disorders [6].
When we started to monitor and study FH, we primarily
dealt with the mechanism of the development of the disease,
and its genetic background and epidemiology [7–9]. As for
the prognosis of patients, there was very little we could do.
There were no options other than selecting the highest-risk
patients with increased concentrations of lipoprotein/a/ (Lp/
a/) [10] and trying to influence the most important risk factor
beyond the scope of pharmacological treatment: the smoking
of cigarettes [11]. However, the situation changed dramatical-
ly at the end of the 1980s, and especially in the 1990s, when
statins were introduced to the market. Statins were widely
used, and initially, their priority use was appropriate for the
treatment of FH [12, 13]. In practice, treatment with statins has
had an immediate impact as shown by a dramatic decrease in
mortality, especially in FH patients under the age of 40
[14–16]. Later, the pharmacotherapy of FH was boosted by
the introduction of ezetimibe [17, 18].
Though effective treatment was possible, interest in FH
was relatively low; this situation led to numerous initiatives,
both on the national and international level, such as the
MedPed (Make Early Diagnosis in Medical Pedigree) project
[19•], and the FH Foundation to name a few [20]. It should be
noted that the Czech Republic, as the lead country of the
described project, became one of the most successful coun-
tries in the identification of FH patients not only in Europe, but
globally [21]. Although these activities were successful, most
patients remained undiagnosed, were treated with low doses
of medicaments, and did not receive the maximum therapy
[22, 23]. In addition, even those patients cared for in special-
ized centers did not often reach the target values and LDL-C
values in FH patients remained high above the upper limit of
normal [24]. Of course, the cardiovascular (CV) risk also
remained very high.
This is why both physician and patient communities in-
volved in the field of FH appreciated the introduction of a
novel generation of medicines into this field. Anti-PCSK9
monoclonal antibodies, also called the biological treatment
for hypercholesterolemia or, simply, PCSK9-inhibitors
(PCSK9-i), introduced the possibility of decreasing LDL-C
levels by 40–60% when used additively to the maximum tol-
erated dose of lipid-lowering drugs [25]. They have been in-
vestigated in various populations, including FH [26]. Not only
do they decrease the levels of LDL-C, but also Lp/a/ which is
another independent risk factor for CV diseases [27, 28].
However, the most important fact in support of the use of these
medicines in the treatment of FH is the results of randomized
clinical studies in tens of thousands of enrolled patients with
evolocumab (Fourier) [29, 30•], as well as those of alirocumab
(Odyssey Outcomes) [31•], which show a reduction in CV
event occurrence in a remarkably short time and, in one sub-
analysis, even a decrease of overall mortality.
Also, the other medications for LDL-C lowering are in
development, e.g., bempedoic acid and others [32]. It means
that potent and powerful therapy becomes available for FH
patients. The identification of FH patients and other highest-
risk patients subsequently became one of the priorities of cur-
rent preventive cardiology and clinical lipidology.
Aim
Clearly, the aim of the project is to improve the identification,
diagnostics, and treatment of FH patients in the regions of
Central, Eastern, and Southern Europe (CESE). The standards
of care for FH patients, as well as the identification of pro-
bands and affected members of families, greatly vary from
country to country in the region. The awareness of FH among
both experts and the general population varies as well.
Therefore, when building the lipid center network and
performing educational activities, exploiting the knowledge
of more successful countries is a deciding factor. The ultimate
objective of the project is the improvement of the lipid profile,
the total CV risk and, finally, the improvement of the patient
prognosis.
Methods
The ScreenPro FH Project is an international project dedicated
to the improvement of complex care—screening, diagnosis,
and treatment of FH in CESE. Originating in seven countries,
it allowed us to identify enthusiastic country leaders and create
national and international networks of lipid centers coordinat-
ed by the project leaders. Individual countries were then set
goals, the first of which was to define the actual situation and
to determine the available treatment. From this point on, the
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project leaders regularly provided each country with informa-
tion and instructions sent electronically or introduced during
business meetings held in conjunction with major internation-
al congresses. With such “central support” (materials, educa-
tion, web-based information), more and more centers and
countries participated in the project.
Upon completion of the three-year project, each country
reported the baseline results (from the beginning of the project)
and results after the inclusion of the patients to the national
database. Nowadays, the basic lipid parameters are available.
Data from individual countries included the number of FH
patients, and averages and standard deviations of lipid parame-
ters from the beginning of the project and after the inclusion of
the patients to the national database. Average values of lipid
parameters of individual countries were summed in relation to
the number of patients, and the difference of the given lipid
parameter values was evaluated. The results were evaluated
using STATISTICA 13 software. All conducted tests were
both-sided. The established level of significance was α = 0.05
in all tests. It must also be stressed that all the data from partic-
ipating countries are aggregate data, not individual patient data.
Description of the Situation in Countries
The countries involved in the ScreenPro FH project comprise
about 500 million inhabitants in total. If we consider the prev-
alence of FH 1:250–500 [33], it constitutes approximately 1–2
million people suffering from this genetic disease. Although
up-to-date results and analyses support the theory that the
occurrence of FH in the overall population is 1:250, the par-
ticipating countries have long estimated a prevalence of 1:500.
The actual number of FH patients is, therefore, much higher in
each individual country, and the rate of diagnosed cases is, on
the contrary, much lower.
Bosnia and Herzegovina
Approximately 7000 people, in a country of 3.5 million, suffer
from FH. Other than the National Centre in Zenica, there are
two more centers operating in Bosnia and Herzegovina. The
number of diagnosed FH patients, or, rather, FH patients reg-
istered in the database, is 1500; there is neither a lipid network
nor patient organization in the country. Potential patients are
selected from hospital databases based on an LDL-C level
higher than 5 mmol/L. Diagnostics is based on the Dutch
Lipid Clinic Network Criteria (DLCNC). The only treatment
available to doctors is statins, with no option of combining
them with ezetimibe or PCSK9-i. LDL apheresis is not an
option in Bosnia and Herzegovina either. The FH program is
focused on educational activities for general practitioners for
children and adults, internists, and ophthalmologists.
Bulgaria
Bulgaria has 7.2 million inhabitants and the estimated number
of FH patients is 14,000. The database compiles data from the
national center, as well as from six other centers, and consists
of 220 patients. The FH program commences at Intensive
Cardiac Care Units, i.e., using patients with previous case
histories of CVD. Diagnostics is based on the DLCNC.
Therapy is based on statins which can be combined with
ezetimibe, and upon achieving six or more points, based on
the DLCNC, patients can also receive PCSK9-i therapy.
Croatia
In a country of 4.2 million inhabitants, the estimated number
of FH patients is approximately 8500 with 150 patients in-
cluded in the database. Croatia boasts a national center at the
University Hospital in Zagreb, and fourmore centers are being
planned. The existing lipid network is based on the MedPed
project which is also the basis of the National MedPed pro-
gram. The DLCNC are applied for the diagnostics of the dis-
ease, with treatment options including not only statins and
ezetimibe but also PCSK9-i or LDL apheresis. Target LDL-
C levels are based on the available recommended methods.
No patient organization has been established in the country.
Czech Republic
The Czech Republic has 10.5 million inhabitants; thus, the
estimated number of potential FH patients is more than
21,000. The country has a rich network of 69 centers includ-
ing national centers in Prague at the General Faculty Hospital
(VFN) and in Brno at St. Anne’s Hospital. These centers are
already cooperating with more than 8000 patients, and the FH
program supported by the Czech Society for Atherosclerosis
cooperates closely with this network of lipid centers.
Coordinators help physicians to operate the centers and to
enter patients into the database. Diagnostics is based on the
modified MedPed criteria with genetic testing available.
Statins, ezetimibe, and PCSK9-i are available for treatment.
Two centers offer also LDL apheresis. A patient organization
was established and operates in the country.
Georgia
There is one center in Georgia, however, whose number of
registered patients is unknown. In this country of 3.7 million
inhabitants, the estimated number of FH patients is 7500.
Greece
Greece has almost 11 million inhabitants, and this corresponds
to an estimated 21,000 FH patients. More than 600 patients
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have been diagnosed and are included in the database. The
national center at the University Hospital in Ioannina cooper-
ates with eight other centers. The FH program is based on a
functioning network of lipid centers contributing to the nation-
al Hellas FH register. The DLCNC are used in diagnostics,
and treatment options include statins, ezetimibe, and PCSK9-
i. Four centers also perform LDL apheresis. A patient organi-
zation is also available for patients.
Hungary
In this country of 9.8 million inhabitants, the estimated occur-
rence of FH patients is 20,000 with 300 patients having been
integrated into the ScreenPro FH database and monitored by
two national centers in Debrecen and Budapest. Genetic anal-
yses, sponsored by scientific grants, are also performed there,
as well as in 18 regional centers. Hungary can be considered a
country with a functioning lipid network. FH is diagnosed
based on the DLCNC, and all the treatment modalities—
statins, ezetimibe, PCSK9-i, and LDL apheresis—are avail-
able; the target levels of LDL-C are 1.8 mmol/L. An umbrella
patient organization was also created for patients.
Kazakhstan
The Republic of Kazakhstan has 18.5 million inhabitants. The
potential number of FH patients can thus be up to 40,000.
Nevertheless, there is no information available on the number
of patients included in the database.
Kyrgyzstan
In Kyrgyzstan, with a population of 5.8 million inhabitants,
the occurrence of FH patients is estimated to be 11,700; these
patients can be monitored in the national center in Bishkek or
in 19 regional centers. The FH program deals with the analysis
of the FH prevalence in patients with a premature manifesta-
tion of CVD, metabolic syndrome, and subsequent primary or
secondary prophylaxis. Three hundred one patients, with di-
agnoses based on the DLCNC, are included in the database.
Treatment options include statins, and LDL apheresis is also
available. No patient organization has been founded yet.
Latvia
With a population of almost 2 million inhabitants, the occur-
rence of FH patients in Latvia is estimated to be approximately
4000, with an aggregate summary of data on 249 patients
reported in the ScreenPro FH registry by the end of
February 2019. Patients are monitored in the national center
in Riga within the frames of the Latvian Registry of FH that
was established in 2015 [34]. The registry currently is not
financed by the government or any other organization, but it
has effectively improved detection of cases from < 0.2% in
early 2015 to more than 3% in early 2019. Index cases are
diagnosed based on the DLCNC. The cascade screening is
performed, and relatives are diagnosed based on 95th percen-
tile of LDL-C. Statins, ezetimibe, and PCSK9-i are available,
but only statins are 50% reimbursed for FH. LDL apheresis is
not performed in this country. There is a working patient or-
ganization “ParSirdi.lv.”
Lebanon
Lebanon’s anticipated rate of FH incidence is 25 times
higher than in Europe; i.e., in a land of 7.8 million inhabi-
tants, the estimated occurrence of FH patients is 15,500,
with only 38 patients included in the database. The higher
incidence can be explained by the so-called founder effect
and by the high number of marriages between blood rela-
tives. A phenomenon called the Lebanese allele was de-
scribed: qualifying FH in up to 81.5% of examined pro-
bands [35, 36]. There is one functioning national center in
the country developing the FH program. Patients can be
offered treatment with statins or ezetimibe; LDL apheresis
is not available in this country, and no patient organization
has been founded yet.
Lithuania
In the Lithuanian population of 2.9 million inhabitants, the
occurrence of approximately 6000 FH patients is projected,
with less than one-third of these patients included in the
ScreenPro FH project. The national center was found in the
capital, Vilnius, and four regional centers are being built. The
Lithuanian High Cardiovascular Risk Primary Prevention
Program (LiTHiR), started in 2006 and covered by health
system, is the base for the functioning lipid network in the
country. More than 250,000 middle-aged adults are screened
every year and receiving primary prophylaxis. Data of >
92,000 individuals is currently included in the electronic da-
tabase for detailed analysis. The prevalence of any dyslipid-
emia (DLP) among these patients is estimated to be 89%, and
the prevalence of any type of severe DLP is 13.4%. The oc-
currence of patients with LDL-C levels ≥ 6mmol/l in screened
population is 3.2%, and in the subgroup of severe DLP, 24%.
FH is diagnosed based on DLCNC. As far as treatment is
concerned, patients can be offered statins, ezetimibe, and
PCSK9-i, as well as LDL apheresis which is performed in
one center. Genetic testing is available. The target is to achieve
LDL-C levels in accordance with current European recom-
mendations for the management of DLP treatment. Patient
organization is being built under the umbrella of Lithuanian
Heart Association.
   36 Page 4 of 12 Curr Atheroscler Rep           (2019) 21:36 
Oman
Oman has a population of 5.2 million inhabitants, and the oc-
currence of FH patients is estimated to be approximately 10
thousand. Thirty-eight patients are included in the database.
Poland
Poland has a population of 38 million inhabitants, and 76,000
FH patients are to be expected, whereas fewer than 2000 have
been diagnosed. Two national centers and seven other centers
contribute to a functioning lipid network. The Polish national
FH program is based on complex care for patients suffering
from lipid metabolism disorders; diagnostics uses the DLCNC
or Simon Broom Criteria. The program is focused on the
selection of high-risk patients with the use of cascade screen-
ing in families with the option of genetic testing also available.
Romania
Almost 20 million people live in Romania, and taking into
account the rates of occurrence we considered, up to 40,000
FH patients are assumed. The actual number of diagnosed
patients is 69. The CardioPrevent Foundation Timisoara is
the national center, and no other centers have been founded
yet. No lipid network exists. Diagnostics is based on the
DLCNC. Statins are available for treatment which can be
combined with ezetimibe or PCSK9-i. LDL apheresis is not
available. Target LDL-C levels depend on the degree of CV
risk. No patient organization has been founded yet.
Russia
In a population of almost 147 million inhabitants, up to
300,000 patients suffering from FH are expected and 1400
FH patients have been successfully introduced to the database.
The national Cardiology Research Center operates in
Moscow, and 27 additional centers contribute to the lipid net-
work. FH is normally diagnosed based on the DLCNC with
DNA diagnostics also available. Treatment options available
in Russia include statins and ezetimibe, as well as PCSK9-i;
10 centers also perform LDL apheresis. A patient organization
is working in the country.
Serbia
Serbia has approximately 7.2 million inhabitants; thus more
than 14,000 FH patients can be expected. Nine hundred of them
have been included in the database. No specific FH program is
available, there are eight regional centers and one national cen-
ter functioning in the country with centralized screening, diag-
nostics, and treatment. Patients are referred to this site primarily
by general practitioners. The DLCNC are used for diagnostics
while statins, ezetimibe, and PCSK9-i are used for treatment,
with LDL apheresis being available.
Slovakia
With a population of 5.4 million inhabitants, we expect up to
11,000 FH patients in Slovakia and more than 2500 of them
are already included in the database. An extensive lipid net-
work is established in the country; apart from the national
center in Bratislava, there are 26 other centers (6 centers for
pediatric patients). FH diagnostics can be performed based on
the DLCNC, the Simon Broom Criteria, or the MedPed
Criteria which is also the base of the Slovak FH program.
Target LDL-C levels are < 2.5 mmol/L for patients in primary
prophylaxis and < 1.8 mmol/L for patients in secondary pro-
phylaxis. These levels can be achieved using statins,
ezetimibe, PCSK9-i, and LDL apheresis. FH patients are unit-
ed in a working patient organization.
Slovenia
In this country with a population of over 2 million people,
more than 4000 FH patients can be expected. More than
50% of the considered number have been diagnosed and are
included in the database. There are two University centers
operating in Slovenia and a specialized network of lipid
clinics. Unfortunately, no more information is available.
Turkey
There are approximately 168,000 FH patients in this land of 84
million people with 3159 patients already integrated into the
ScreenPro FH project database. As far as the management of
the treatment of patients is concerned, there is a national center
in Izmir and 31 regional centers. The FH program is based on
the Adult HoFH Apheresis Registry, and the creation of a func-
tioning lipid network (which had not existed in the county until
now) is being planned. The diagnosis of FH is made based on
the DLCNC; treatment modalities are represented not only by
statins, ezetimibe, or evolocumab (only for patients with homo-
zygous FH) but also by LDL apheresis which is performed in
18 centers. Patients are treated to achieve target LDL-C levels
of compliancy described by current European guidelines. There
is also a working patient organization in the country.
Ukraine
In Ukraine, with a population of 43 million inhabitants, the
occurrence of approximately 86,000 FH cases can be expect-
ed; 147 patients have been included in the ScreenPro FH da-
tabase so far. A lipid network is being developed in the coun-
try to include a national center and four regional centers. The
objective of the FH program in the country is to actively
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search for patients with suspected FH; FH should be diag-
nosed with the use of the DLCNC or Simon Broom Criteria.
Patients can be treated with statins and ezetimibe to achieve
the target LDL-C levels of less than 1.8 mmol/L and
2.5 mmol/L, respectively, based on the category of CV risk.
LDL apheresis is not available, and no patient organization
has been founded in the country yet.
Uzbekistan
The occurrence of potential FH patients in Uzbekistan, with a
population of 31 million inhabitants, is estimated to be 62,000,
though there are only 106 cases in the ScreenPro FH project
database. A lipid network has been created in the country, albeit
at a slow pace, with the national center in Tashkent and four
regional centers. The objective of the FH program is to introduce
a personalized approach to the treatment of DLP patients. In these
patients, the diagnosis is established based on the DLCNC; not
only is treatment available with statins, but also with LDL aphe-
resiswhich can be performed at two private clinics. Target LDL-C
levels are set to 1.8 mmol/L. Patients with a diagnosis of FH can
also register in a patient organization under the auspices of the
Republican Specialized Center of Cardiology (RSCC).
Results
Ten of the 22 countries of the CESE region took part in the
project to search for FH patients and investigated the effect of
the care for these patients in specialized regional center net-
works on the levels of total cholesterol, triglycerides, LDL-C,
and HDL-cholesterol (HDL-C). These countries included the
Czech Republic, Bosnia and Herzegovina, Lithuania, Latvia,
Hungary, Russia, Serbia, Slovakia, Uzbekistan, and Ukraine.
During the project, levels of lipid parameters were subse-
quently obtained from 5585 of the 9065 monitored patients.
In all countries, with the exception of Ukraine, the levels of
total cholesterol, triglycerides, and LDL-C during the project
were always statistically significantly lower (p < 0.001) than
at their inclusion in the project. A substantial decrease of ap-
proximately 41.5% was noticed in LDL-C levels and by
approximately 32% in total cholesterol levels (Table 1). The
decrease in the triglyceride levels in the monitored countries
was approximately 16% while there was almost no difference
in the HDL-C levels.
Patient representation was markedly different in each of the
10 countries (Appendix Table 6). In the Czech Republic, only
3256 patients, from the original group of 4045 patients included
in the project, were continuously monitored. This situation was
similar in Russia and Slovakia, where 699 patients from the
original group of 1200 patients and 200 patients from the original
group of 2246 patients, respectively, were continuously moni-
tored. In Bosnia and Herzegovina, 343 patients were included in
the project and continuously monitored. Similarly in Serbia,
Uzbekistan, andUkraine, the number of patients monitored were
302, 106, and 147 respectively. Small differences between the
numbers of monitored patients at the project entrance in compar-
ison with the number of patients monitored during the project
were seen in Lithuania, Latvia, and Hungary. In Lithuania, there
were 98 patients included in the project and this number in-
creased up to 100 patients in the course of the study. In Latvia,
there were 249 patients included in the project and 105 patients
had at least one follow-up visit. In Hungary, there were 329
patients included in the study and 327 patients continued; thus,
a minimum decrease of patients was observed.
The levels of triglycerides and HDL-C were compared in
only nine selected countries (Tables 2 and 3). Hungary was
not included in the comparison of these two lipid parameters.
However, the levels of total cholesterol and LDL-C were com-
pared in all selected countries (Tables 4 and 5). The decreases in
the levels of total cholesterol, LDL-C, and triglycerides were
statistically significant in all selected countries with the excep-
tion of Ukraine (p < 0.001) where a statistically significant de-
crease was found only in the triglyceride levels (p < 0.001). The
decreases in the levels of total cholesterol and LDL-C were not
statistically significant (p = 0.276 and p = 0.068, respectively)
in Ukraine, though a decrease in the values of these two lipid
parameters was reported. As far as total cholesterol is con-
cerned, a significant decrease in its levels was observed in
Bosnia and Herzegovina, and Latvia (Fig. 2), in particular,
where the values of total cholesterol decreased by more than
40%. Decreases in levels of total cholesterol by approximately
Table 1 Effect of screening and
treatment on the lipid parameter









Cholesterol concentration (mmol/L) 8.640 5.850 2.790 32.30%
LDL-C concentration (mmol/L) 6.220 3.640 2.580 41.52%
Triglyceride concentration (mmol/L) 1.820 1.530 0.290 15.84%
HDL-C concentration (mmol/L) 1.438 1.437 0.001 0.04%
LDL-C LDL-cholesterol, HDL-C HDL-cholesterol. Average values of lipid parameters of individual countries
from the beginning of the project and after the inclusion of the patients to the national database were summed and
related to the number of patients, and the difference of the given lipid parameter values was evaluated; this
difference was related to the total level of lipid parameter at the start of the project
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35% were also observed in the Czech Republic and Hungary,
and by 25–30% in Slovakia and Uzbekistan. Decreases of ap-
proximately 20% were reported in Russia, Serbia, and
Lithuania. A 3.6% decrease in the levels of total cholesterol
was observed in Ukraine. Significant decreases in LDL-C
levels were observed in the Czech Republic, Latvia, Hungary,
and Uzbekistan where the levels of LDL-C decreased by more
than 40% (Fig. 1). Decreases in LDL-C levels of approximately
25–35% were reported in Bosnia and Herzegovina, Lithuania,
Russia, and Slovakia. Only in Serbia andUkraine did the values
of LDL-C decrease by approximately 20% and 7.8%, respec-
tively. In Bosnia and Herzegovina as in Latvia, the triglyceride
levels significantly decreased by more than 35%. In Lithuania
and Uzbekistan, the triglyceride levels decreased by 26–31%
(Fig. 3). Slight decreases, 18–21%, in the levels of triglycerides
were observed in the Czech Republic and Ukraine, and by no
more than 13% in Russia, Serbia, and Slovakia.
In the case of HDL-C, statistically significant lower levels,
when compared with the baseline values, were found in
Lithuania (from 1.3 to 1.2, p = 0.027) and Latvia (a decrease
from 1.69 to 1.49, p = 0.004), and statistically significant
higher levels were found in Slovakia (an increase from 1.4
to 1.5, p = 0.008) and Uzbekistan (an increase from 1.0 to
1.1, p = 0.041). In the Czech Republic, Bosnia and
Herzegovina, Russia, Serbia, and Ukraine, the baseline
HDL-C levels remained almost the same during the project
in comparison with the baseline (Fig. 4).
Discussion
The ScreenPro FH is not the only international activity in the
field of FH. In the Pacific region, a similar project, the “Ten
Table 2 Comparison of triglyceride values at the project entrance and
during the project in individual countries
Triglyceride
concentration (mmol/L)
Start of the project Follow-up p value
Mean SD Mean SD
Czech Republic 1.75 0.81 1.43 0.83 p < 0.001
Bosnia and Herzegovina 2.35 1.63 1.48 0.50 p < 0.001
Lithuania 2.30 1.80 1.70 1.00 p < 0.001
Latvia 2.10 1.46 1.24 0.60 p < 0.001
Hungary
Russia 1.90 1.20 1.70 1.00 p < 0.001
Serbia 2.09 0.99 1.84 0.82 p < 0.001
Slovakia 1.60 0.70 1.40 0.70 p < 0.001
Uzbekistan 4.20 0.70 2.90 0.80 p < 0.001
Ukraine 2.30 0.93 1.83 0.93 p < 0.001
SD standard deviation
Table 3 Comparison of HDL-C values at the project entrance and
during the project in individual countries
HDL-C concentration
(mmol/L)
Start of the project Follow-up p value
Mean SD Mean SD
Czech Republic 1.52 0.47 1.52 0.41 p = 1.000
Bosnia and Herzegovina 1.03 0.33 1.00 0.22 p = 0.162
Lithuania 1.30 0.40 1.20 0.20 p = 0.027
Latvia 1.69 0.65 1.49 0.42 p = 0.004
Hungary
Russia 1.40 0.50 1.40 0.40 p = 1.000
Serbia 1.32 0.37 1.34 0.45 p = 0.551
Slovakia 1.40 0.50 1.50 0.60 p = 0.008
Uzbekistan 1.00 0.40 1.10 0.30 p = 0.041
Ukraine 1.23 0.33 1.28 0.33 p = 0.195
HDL-C HDL-cholesterol, SD standard deviation
Table 4 Comparison of total cholesterol values at the project entrance
and during the project in individual countries
Cholesterol concentration
(mmol/L)
Start of the project Follow-up p value
Mean SD Mean SD
Czech Republic 8.77 1.57 5.54 1.43 p < 0.001
Bosnia and Herzegovina 7.60 1.43 3.95 0.86 p < 0.001
Lithuania 8.20 2.10 6.60 1.10 p < 0.001
Latvia 9.73 2.70 5.60 2.04 p < 0.001
Hungary 9.00 2.44 5.92 2.61 p < 0.001
Russia 9.20 2.00 7.40 2.30 p < 0.001
Serbia 6.87 1.93 5.91 1.39 p < 0.001
Slovakia 8.30 1.40 6.00 1.60 p < 0.001
Uzbekistan 9.20 2.70 6.30 1.80 p < 0.001
Ukraine 8.92 2.58 8.60 2.43 p = 0.276
SD standard deviation
Table 5 Comparison of LDL-C values at the project entrance and
during the project in individual countries
LDL-C concentration
(mmol/L)
Start of the project Follow-up p value
Mean SD Mean SD
Czech Republic 6.46 1.53 3.37 1.33 p < 0.001
Bosnia and Herzegovina 3.33 1.15 2.40 0.84 p < 0.001
Lithuania 5.60 2.10 4.20 1.20 p < 0.001
Latvia 7.19 1.86 3.53 1.78 p < 0.001
Hungary 5.98 2.34 3.42 2.25 p < 0.001
Russia 6.90 1.70 4.90 2.40 p < 0.001
Serbia 4.51 1.69 3.61 1.19 p < 0.001
Slovakia 6.00 1.40 3.90 1.50 p < 0.001
Uzbekistan 6.50 1.70 3.70 1.10 p < 0.001
Ukraine 6.83 2.48 6.30 2.48 p = 0.068
LDL-C LDL-cholesterol, SD standard deviation
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Countries Study,” was carried out, with similar intentions and
results [37, 38]. The biggest and only true global project is the
FHSC [39]. It intends to create a global database which would
be optimal both for data collection and their quality. On the
other hand, there are mainly legal obstacles (of all kinds) in
several countries which slow the recruitment of patients. Our
study uses data summarized for each country. Consequently,
the data of individual patients are not, for all intents and pur-
poses, released from home countries. This explains why our
group of FH patients is one of the biggest groups when com-
pared with the global database.
The most valuable result of our project is considered to be
the significant (not only statistically but mainly clinically)
change in the lipid spectrum, in particular the decrease in
LDL-C levels by more than 40% and the decrease of total
cholesterol levels by more than 30% in patients from their
inclusion to the database to post-intervention. Thus, we con-
sider the results undoubtedly positive, despite the fact that we
were not able to include results from all patients in the data-
bases due to the lack of “before and after” data.
However, it must be stated that our results have only lim-
ited validity. In addition, it is necessary to mention that our
patients are far from the target levels of LDL-C and total
cholesterol. Nonetheless, this represents the first analysis; in
many centers, physicians have a great opportunity to use
higher doses of lipid-lowering drugs. Also, it will soon be
possible, at least in some countries, to introduce monoclonal
antibodies, evolocumab, and alirocumab. Regarding the
change in triglycerides, although it is positive, we do not con-
sider it significant. The change in HDL-C, which is minimal
from a clinical point of view, is not considered substantial.
So far in the project, we have not paid much attention to
treatment with LDL apheresis which is available in some
countries; however, it can be considered highly selective and
often aimed only at FH homozygotes.
Conclusions
As pointed out several times in the past, FH represents a sig-
nificant CVrisk. On the other hand, there are several treatment
options: currently available standard treatment (statins +
ezetimibe) and up-to-date treatment, MAB (PCSK9-i), as well
as bempedoic acid [32], which is currently in development, or
inclisiran. The search for patients and their early treatment is
thus legitimate. The ScreenPro FH project exemplifies the
benefits of the contributions of an international community
to improving screening, diagnostics, and treatment of FH pa-
tients. It is further proof that sharing information, assisting in
education, and increasing awareness can lead to positive
changes in lipids, especially to a significant decrease in
LDL-C in FH patients.
It can be generally concluded that the international
cooperation in the ScreenPro FH project has led to a
decrease in the CV risk in FH patients included in na-
tional databases. In further studies, we would like to
focus on two issues in particular.
1. To increase the number of patients included in national
databases



















































Fig. 1 Comparison of LDL-C
Levels at the project entrance and
during the project in individual
countries
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(b) By increasing awareness in both the general popula-
tion and among medical experts
(c) By supporting patient organizations in individual
countries
2. To improve FH patients’ comprehensive treatment and im-
prove the effects of the treatment with lipid-lowering drugs,
so that, in optimal cases, the target values are achieved
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Appendix
Table 6 Comparison of lipid parameter values at the project entrance and during the project in individual countries
Country Start of the project Follow-up p value
Mean SD Mean SD
Czech Republic 4045 patients 3256 patients
Cholesterol concentration (mmol/L) 8.77 1.57 5.54 1.43 p < 0.001
LDL-C concentration (mmol/L) 6.46 1.53 3.37 1.33 p < 0.001
Triglyceride concentration (mmol/L) 1.75 0.81 1.43 0.83 p < 0.001
HDL-C concentration (mmol/L) 1.52 0.47 1.52 0.41 p = 1.000
Bosnia and Herzegovina 343 patients 343 patients
Cholesterol concentration (mmol/L) 7.60 1.43 3.95 0.86 p < 0.001
LDL-C concentration (mmol/L) 3.33 1.15 2.40 0.84 p < 0.001
Triglyceride concentration (mmol/L) 2.35 1.63 1.48 0.50 p < 0.001
HDL-C concentration (mmol/L) 1.03 0.33 1.00 0.22 p = 0.162
Lithuania 98 patients 100 patients
Cholesterol concentration (mmol/L) 8.2 2.1 6.6 1.1 p < 0.001
LDL-C concentration (mmol/L) 5.6 2.1 4.2 1.2 p < 0.001
Triglyceride concentration (mmol/L) 2.3 1.8 1.7 1.0 p < 0.001
HDL-C concentration (mmol/L) 1.3 0.4 1.2 0.2 p = 0.027
Latvia 249 patients 105 patients
Cholesterol concentration (mmol/L) 9.73 2.70 5.60 2.04 p < 0.001
LDL-C concentration (mmol/L) 7.19 1.86 3.53 1.78 p < 0.001
Triglyceride concentration (mmol/L) 2.10 1.46 1.24 0.60 p < 0.001
HDL-C concentration (mmol/L) 1.69 0.65 1.49 0.42 p = 0.004
Hungary 329 patients 327 patients
Cholesterol concentration (mmol/L) 9.00 2.44 5.92 2.61 p < 0.001
LDL-C concentration (mmol/L) 5.98 2.34 3.42 2.25 p < 0.001
Triglyceride concentration (mmol/L)
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Table 6 (continued)
Country Start of the project Follow-up p value
Mean SD Mean SD
HDL-C concentration (mmol/L)
Russia 1200 patients 699 patients
Cholesterol concentration (mmol/L) 9.2 2.0 7.4 2.3 p < 0.001
LDL-C concentration (mmol/L) 6.9 1.7 4.9 2.4 p < 0.001
Triglyceride concentration (mmol/L) 1.9 1.2 1.7 1.0 p < 0.001
HDL-C concentration (mmol/L) 1.4 0.5 1.4 0.4 p = 1.000
Serbia 302 patients 302 patients
Cholesterol concentration (mmol/L) 6.87 1.93 5.91 1.39 p < 0.001
LDL-C concentration (mmol/L) 4.51 1.69 3.61 1.19 p < 0.001
Triglyceride concentration (mmol/L) 2.09 0.99 1.84 0.82 p < 0.001
HDL-C concentration (mmol/L) 1.32 0.37 1.34 0.45 p = 0.551
Slovakia 2246 patients 200 patients
Cholesterol concentration (mmol/L) 8.3 1.4 6.0 1.6 p < 0.001
LDL-C concentration (mmol/L) 6.0 1.4 3.9 1.5 p < 0.001
Triglyceride concentration (mmol/L) 1.6 0.7 1.4 0.7 p < 0.001
HDL-C concentration (mmol/L) 1.4 0.5 1.5 0.6 p = 0.008
Uzbekistan 106 patients 106 patients
Cholesterol concentration (mmol/L) 9.2 2.7 6.3 1.8 p < 0.001
LDL-C concentration (mmol/L) 6.5 1.7 3.7 1.1 p < 0.001
Triglyceride concentration (mmol/L) 4.2 0.7 2.9 0.8 p < 0.001
HDL-C concentration (mmol/L) 1.0 0.4 1.1 0.3 p = 0.041
Ukraine 147 patients 147 patients
Cholesterol concentration (mmol/L) 8.92 2.58 8.60 2.43 p = 0.276
LDL-C concentration (mmol/L) 6.83 2.48 6.30 2.48 p = 0.068
Triglyceride concentration (mmol/L) 2.30 0.93 1.83 0.93 p < 0.001
HDL-C concentration (mmol/L) 1.23 0.33 1.28 0.33 p = 0.195











































Fig. 3 Comparison of triglyceride levels at the project entrance and









































Fig. 2 Comparison of total cholesterol levels at the project entrance and
during the project in individual countries
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